Considerations for the Management of Overactive Bladder in Long-Term Care

This clinical brief is supported by Sumitomo Pharma America.

This information is intended solely for payer and formulary decision makers and is provided for informational purposes regarding reimbursement and healthcare decision-making. This material is non-promotional and should not be distributed or used for promotional purposes.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Considerations for the Management of Overactive Bladder in Long-Term Care

Trending on AJMC

DOJ Abandons Olmstead Defense as Texas v Kennedy Advances

FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes

Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis

FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera

Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk